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Background and aims: Bacteroides vulgatus induces colitis in gnotobiotic HLA- B27 transgenic (TG)
rats while broad spectrum antibiotics prevent and treat colitis in specific pathogen free (SPF) TG rats
although disease recurs after treatment ends. Lactobacilli treat human pouchitis and experimental coli-
tis. We investigated if Lactobacillus rhamnosus GG (L GG) can prevent colitis in TG rats monoassoci-
ated with B vulgatus and if L GG or Lactobacillus plantarum 299v (LP 299v) can treat established colitis
in SPF TG rats and prevent recurrent disease after antibiotics were stopped.
Methods: Germfree B27 TG rats were monoassociated with B vulgatus for four weeks following two
weeks of colonisation with L GG or no bacteria. SPF B27 TG rats received oral vancomycin and imi-
penem for two weeks, or water alone, followed by four weeks of treatment with oral L GG, LP 299v, or
water only. Disease activity was quantified by blinded gross and histological scores, caecal myeloper-
oxidase (MPO) activity, and levels of interleukin (IL)-1β, tumour necrosis factor (TNF), transforming
growth factor β, and IL-10.
Results: L GG did not prevent colitis in B vulgatus co-associated TG rats or treat established disease
in SPF rats. However, L GG but not LP 299v prevented colitis relapse in antibiotic treated rats with
reduced gross and histological scores, caecal MPO, IL-1β, and TNF whereas caecal IL-10 was
increased.
Conclusions: L GG does not prevent colitis in gnotobiotic TG rats or treat established disease in SPF
rats, but is superior to LP 299v in the prevention of recurrent colitis. These studies suggest that anti-
biotics and probiotic agents provide synergistic therapeutic effects, perhaps mediated by altered
immunomodulation with selective activity of different lactobacillus species.
The role of intestinal bacteria in the pathogenesis of humaninflammatory bowel diseases (IBD), particularly Crohn’sdisease, is well recognised.1 2 These diseases typically occur
at sites with the highest concentrations of intestinal bacteria,
such as the colon and terminal ileum. Antibiotics and faecal
diversion are effective treatment modalities for Crohn’s
disease1–3 whereas re-establishing continuity of the bypassed
distal bowel or infusion of intestinal contents into the
excluded ileum leads to disease recurrence.4
The role of intestinal bacteria in the initiation and perpetu-
ation of chronic intestinal inflammation is most convincingly
demonstrated in experimental models of chronic intestinal
inflammation in which genetically susceptible hosts develop
spontaneous colitis in the presence of commensal intestinal
organisms whereas no disease occurs in the germ free (GF)
state.5–8
HLA-B27 transgenic (TG) rats develop colitis, gastritis, and
systemic inflammation in a specific pathogen free (SPF)
environment.9 However, GF TG rats and non-TG rats colonised
with SPF bacteria show no evidence of colitis, gastritis, or
arthritis.5 10 Colitis and gastroduodenal inflammation in TG
rats is attenuated by metronidazole therapy and can be
prevented and treated with broad spectrum antibiotics.11
Moreover, caecal bacterial overgrowth within an experimental
blind loop exacerbates colitis whereas bypass of the caecum
attenuates disease in this model, which correlates with
concentrations of luminal bacteroides species.12 Bacteroides vul-
gatus preferentially induces colitis in TG rats after monoasso-
ciation for four weeks13 whereas monoassociation with
Escherichia coli does not cause disease. These findings indicate
that not all bacteria are equal in their capacity to induce coli-
tis.
Probiotics are defined as living commensal micro-
organisms which are important to the health and well being of
the host.14 Lactobacilli, although not predominant enteric
organisms, are present throughout the gastrointestinal tract of
healthy humans and rodents. Several lactobacillus strains,
such as L plantarum 299v (LP 299v), L acidophilus, L fermentum,
and Lactobacillus rhamnosus GG (L GG) can colonise the human
gastrointestinal tract.15 Several human clinical trials have
shown the efficacy of several species of probiotics in viral and
bacterial induced infectious colitis as well as in antibiotic
associated diarrhoea.14 16 17 Rectal administration of native
murine L reuteri prevented colitis in interleukin (IL)-10
deficient mice and a similar effect was shown by the oral
prebiotic lactulose, which stimulated the growth of endog-
enous lactobacilli species.18 Continuous oral treatment of LP
299v in GF IL-10 deficient mice colonised with SPF flora
attenuated established colitis.19 A probiotic preparation in-
cluding four species of lactobacilli, three bifidobacteria, and
one Streptococcus salivarius (VSL# 3) maintained remission of
refractory pouchitis after transient antibiotic therapy.20 This
probiotic cocktail VSL#3 was also beneficial in the treatment
of colitis in IL-10 deficient mice.21
The first aim of our study was to investigate if the probiotic
species L GG can prevent colitis in B27 TG rats monoassociated
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with the disease inducing B vulgatus. Secondly, we determined
if L GG or LP 299v could treat established colitis in SPF B27 TG
rats or prevent recurrent disease after broad spectrum anti-
biotics were stopped. Thirdly, we studied the protective
mechanisms of probiotics in the prevention of relapse model.
MATERIALS AND METHODS
Rats
TG rats of the 33-3 line on an inbred F344 background, bear-
ing several copies of the genes for HLA-B27 and human β2
microglobulin,9 and their non-transgenic littermates were
originally obtained from Dr Joel Taurog, Southwestern Medi-
cal School (Dallas, Texas, USA). After caesarean section they
were housed in Trexler isolators in GF conditions at the
Gnotobiotic Core facility at the College of Veterinary Medicine
(Raleigh, North Carolina, USA). SPF TG rats and their non-TG
littermates were born and maintained in filter top cages in a
pathogen free environment.
Bacteria
Freeze dried cultures of L GG and LP 299v were kindly provided
by ConAgra (Omaha, Nebraska, USA).
Before administration, lactobacilli strains were grown aero-
bically overnight at 37°C in MRS broth. The next day bacteria
were harvested by centrifugation. After washes, bacteria were
resuspended in sterile phosphate buffered saline (PBS) and
added to the drinking water. Quantification and purity of bac-
terial suspensions as bacterial colony forming units (CFU)
was performed in serial dilutions of the drinking water on
lactobacillus MRS-vancomycin plates. B vulgatus was kindly
provided by Dr AB Onderdonk (Harvard University, Cam-
bridge, Massachusetts, USA) and was originally derived from
guinea pigs with carrageenan induced colitis.22 This strain has
been used to induce colitis in monoassociated TG rats.13 B vul-
gatus was cultured anaerobically in BHI broth before colonisa-
tion of gnotobiotic rats.
Experimental design
Prevention study
In the first part of the study, GF TG rats and their non-TG lit-
termates were divided into three groups of six rats each at the
age of two months. The first two groups were monoassociated
with either B vulgatus or L GG for four weeks, the third group
was selectively colonised with B vulgatus for four weeks but
was colonised with L GG for two weeks before co-colonisation
with B vulgatus. Colonisation with B vulgatus was performed by
oral and rectal swabbing using stool from other B vulgatus
monoassociated rats. L GG or LP 299v was administered once
in the drinking water at 1010 CFU per rat per day after
overnight culture at 37°C in MRS broth. The amount of bacte-
ria consumed by each rat per day was calculated by measured
consumption of 30 ml of water per day times 3.3×108
CFU/ml=1010 CFU. Successful colonisation was assessed after
one week by plating stool suspensions on bacteroides bile
esculin (BBE) and MRS plates for bacteroides spp and
lactobacillus, respectively, for two days of anaerobic culture, as
well as by performing Gram stains. No contaminating organ-
isms were discovered. Rats were killed after four weeks of B
vulgatus or L GG colonisation. At necropsy caeca and colons
were fixed in 10% buffered formalin for histological evalua-
tions. Caeca were also snap frozen for subsequent myeloper-
oxidase (MPO) and cytokine analysis. Caecal contents were
collected for microbiological analysis, as described below.
Prevention of relapse study
At 10 weeks of age, SPF HLA-B27 TG rats were divided into the
following four treatment groups, each consisting of six rats:
group 1 received only drinking water ad libitum for six weeks;
group 2 received 50 mg/kg each of vancomycin/imipenem in
their drinking water for two weeks followed by four weeks of
water; group 3 received 50 mg/kg each of vancomycin/
imipenem for two weeks followed by daily administration of L
GG or LP 299v in the drinking water at 1010 CFU/rat/day for
four weeks; and group 4 received two weeks of water followed
by four weeks of 1010 CFU/rat/day L GG or LP 299v in their
drinking water. All rats were killed six weeks after the start of
treatment. Caeca and colons were collected for histology and
snap frozen for MPO and cytokine analysis, as described
below. Caecal contents were collected for quantitative micro-
biological analysis.
Histology
Tissues were prepared as previously described.10 A validated
histological inflammatory score ranging from 0 to 4 was used
for blinded evaluation of colonic and caecal inflammation.10
Caecal cytokine analysis
Frozen caecal tissues were thawed and lysed in PBS contain-
ing a cocktail of protease inhibitors (antipain, aprotinin,
leupeptin, pepstatin A, all at 1 µg/ml and 1 mM PMSF; Sigma,
St Louis, Missouri, USA).23 Tissue was then homogenised,
after which the homogenate was assayed for IL-1β, tumour
necrosis factor (TNF), IL-10, and transforming growth factor β
(TGF- β). Concentrations of IL-1β were measured by a rat
IL-1β enzyme linked immunosorbent assay (ELISA) devel-
oped by S Poole, as described previously.10 Caecal TNF and
IL-10 concentrations were determined by rat cytokine specific
ELISAs. TGF-β1 concentrations were measured after acidifica-
tion and neutralisation according to the manufacturer using a
TGF-β1 specific ELISA (Promega, Madison, Wisconsin, USA)
MPO assay
Homogenised caeca were assayed for MPO activity (units per
gram of tissue), as described previously.24
Determination of caecal bacterial concentrations
Caecal contents were removed aseptically, immediately placed
into an anaerobic chamber, and dissolved in sterile pre-
reduced PBS. Serial 100-fold dilutions were plated and
cultured anaerobically for two days on lactobacilli spp MRS
vancomycin agar for quantification of lactobacillus, on BBE
agar plates for bacteroides spp, and on Brucella agar (Remel,
Lenexa, KS) for total anaerobic bacteria. Morphology was
determined by Gram stain. Results are expressed as CFU per
gram caecal contents dry weight.
Inhibition of in vitro adherence to IEC-6 cells
The rat epithelial cell line IEC-6 cells (ATCC # CRL 1592;
Rockville, Maryland, USA) were grown to confluence in a 12
well tissue culture plate in antibiotic free Dulbecco’s modified
Eagle’s medium containing 5% heat inactivated newborn
bovine serum and 10 IU (international units)/ml insulin (Life
Technologies, Burlington, Ontario, Canada).
Intestinal epithelial adherence assay was performed accord-
ing to Mack and colleagues.25 Briefly, after removal of
non-adherent cells, an adherent IEC-6 monolayer was
incubated at 37°C with 109 CFU B vulgatus in the presence or
absence of 109, 108, or 107 CFU L GG per well in 2 ml of
antibiotic free complete medium under aerobic conditions.
After three hours of incubation, non-adherent bacteria were
removed by washing three times with warm PBS, IEC-6 cells
plus adherent bacteria were collected by trypsinisation.
Collected cells and adherent bacteria were then serially
diluted and plated anaerobically on BHI plates for 48 hours.
Bacteria were counted by colony identification, confirmed by
Gram staining.
Statistical analysis
Statistics were performed using the Student’s t test or Mann-
Whitney test for comparison between groups. Significance
was considered to be p<0.05. All data are presented as mean
(SEM).




Monoassociation of TG rats with B vulgatus resulted in mild
caecal and colonic inflammation (histology score for the cae-
cum 1.5 (0.1) and colon 1.2 (0.1)). However, pretreatment of
GF TG with L GG followed after two weeks by co-association
with B vulgatus did not prevent the development of mild colitis
induced by B vulgatus (histology scores for the caecum 1.6
(0.2) and colon 1.1 (0.2)). However, monoassociation of
gnotobiotic TG rats with L GG did not induce colitis (caecal
and colonic scores both 0.2 (0.1)). Similarly, gnotobiotic
non-TG rats colonised with B vulgatus, L GG, or both did not
develop colitis (histology score for the caecum or colon 0.2
(0.1)).
Caecal IL-1β concentrations from B vulgatus monoassoci-
ated TG rats (12 (3) pg/mg caecal wet weight) were not
significantly different from those obtained from B vulgatus and
L GG co- associated TG rats (11 (2) pg/mg). Caecal IL-1 β con-
centrations from L GG monoassociated TG rats (5 (2) ng/g)
were similar to those from gnotobiotic non-TG littermates
colonised with B vulgatus, L GG, or both (2 (1) pg/mg).
The concentration of bacteroides spp in the caecal content
of TG rats co-associated with B vulgatus and L GG did not dif-
fer significantly from B vulgatus monoassociated TG rats (61
(8)×109 versus 47 (4)×109 CFU/g caecal content in B vulgatus
and B vulgatus plus L GG associated TG rats, respectively). The
concentration of caecal L GG (0.45 (0.04)×109 CFU/g) in the B
vulgatus plus L GG co-associated rats was 100-fold lower than
B vulgatus concentrations but did not differ significantly from
the concentration of caecal L GG in L GG monoassociated TG
Figure 1 Gross gut scores (0–4) of caeca from specific pathogen
free (SPF) transgenic (TG) rats treated with vancomycin/imipenem
(Abs) or water followed by oral Lactobacillus rhamnosus GG (L GG)
or water administration. Gross gut scores from untreated SPF TG rats
are also given. Each group consisted of six rats. Data are expressed



















Figure 2 Representative photomicrographs of tissue sections (×40) from caeca of 16 week old specific pathogen free (SPF) transgenic (TG)
rats which were treated with: (A) water; (B) two weeks oral vancomycin/imipenem followed by four weeks of water; (C) two weeks oral of
vancomycin/imipenem followed by daily administration of Lactobacillus rhamnosus GG (L GG) over four weeks; and (D) two weeks of water
followed by four weeks of oral L GG. Note the extensive mucosal and some submucosal inflammation as well as significant crypt hyperplasia in
caeca in (A), (B), and (D). Only mild to modest mucosal inflammation was seen in TG rats treated with the combination of broad spectrum
antibiotics followed by L GG (C).
Figure 3 Blinded total colonic inflammatory scores in specific
pathogen free (SPF) transgenic (TG) rats treated for two weeks with
oral broad spectrum antibiotics (Abs) or water followed by four
weeks of Lactobacillus rhamnosus GG (L GG), Lactobacillus
plantarum strain 299v (L pl), or water. Also, histology scores from
SPF TG untreated rats are given. Values represent mean (SEM) of
total histology scores (0–4). Vancomycin/imipenem followed by
daily oral L GG administration significantly decreased total colonic
histology scores versus other treatment groups. Feeding LP 299v did
not prevent colitis relapse nor did it treat established colitis. *p<0.05

























372 Dieleman, Goerres, Arends, et al
www.gutjnl.com
rats (0.49 (0.10)×109 CFU/g). Gram staining, and aerobic and
anaerobic culture of caecal contents from gnotobiotic rats
excluded contamination with other organisms.
Prevention of colitis relapse in SPF B27 TG rats
Oral administration of broad spectrum antibiotics (oral
imipenem/vancomycin) for two weeks to SPF B27 TG rats fol-
lowed by cessation of this treatment resulted in relapse of
colitis after four weeks. Caecal gross gut scores (1.7 (0.2)) as
well as total colonic histology scores (1.7 (0.2)) of antibiotic-
water treated rats four weeks after stopping antibiotics did not
differ from untreated control TG animals (caecal gross score
1.7 (0.2), total colonic histology score 1.7 (0.1)) (figs 1–3).
Also, L GG administration alone could not effectively treat dis-
ease (caecal gross score 1.3 (0.3), total colonic histology score
1.8 (0.2)). However, if antibiotic treatment was followed by
daily oral administration of L GG, relapse of colitis could be
partially prevented, as shown by a significant decrease in cae-
cal gross score (0.6 (0.1)) and total colonic histological
inflammatory score (1.1 (0.3)) of this treatment group (figs
1–3). In contrast with L GG treatment, oral administration of
LP 299v alone or after antibiotic treatment had no effect; nei-
ther caecal gross scores (data not shown) nor colonic histology
scores (fig 3) differed significantly between treatment groups.
Caecal MPO values reflected the gross and histological
scores; only TG rats treated with antibiotics followed by L GG
showed a significant reduction in caecal MPO (5.6 (1.0) U/g
tissue) versus all other treatment groups whereas MPO in
caecal homogenates from TG rats treated with antibiotics
alone (20.3 (5.6) U/g) or with L GG alone (10.2 (1.4) U/g) did
not differ from untreated TG controls (13.3 (3.7) U/g) (fig 4).
Caecal MPO from TG rats which had been fed L plantarum
with or without antibiotic pretreatment did not differ signifi-
cantly from other treatment groups (data not shown).
Mucosal cytokines
Caecal homogenates from SPF TG rats treated with antibiotics
and/or L GG contained significantly less IL-1β than the other
treatment groups (fig 5A). A similar pattern was shown for
caecal TNF, although TNF concentrations were about 10-fold
less than caecal IL-1β (fig 5B). Interestingly, IL-10 concentra-
tions were significantly increased in caecal homogenates from
antibiotics-L GG treated TG rats versus other treatment groups
whereas caecal TGF-β levels were no different among the
groups (fig 5B).
Bacteriology of caecal contents
No differences were found in total bacterial counts of caecal
contents between the antibiotic and/or L GG treatment groups
in SPF TG rats. Also, concentrations of caecal anaerobic and
aerobic bacteria, as determined by culture on Brucella and
Figure 4 Caecal myeloperoxidase (MPO) concentrations in
specific pathogen free (SPF) transgenic (TG) rats treated for two
weeks with oral broad spectrum antibiotics (Abs) or water followed
by four weeks of Lactobacillus rhamnosus GG (L GG), or water.
Values from untreated TG control rats are also given. Data represent

























Figure 5 Caecal interleukin (IL)-1β (A), and tumour necrosis factor (TNF), IL-10, and transforming growth factor β (TGF-β) (B) concentrations
(pg/mg) from transgenic (TG) rats treated for two weeks with oral broad spectrum antibiotics (Abs) or water followed by four weeks of
Lactobacillus rhamnosus GG (L GG) or water as well as from untreated controls. Values are mean (SEM). *p<0.05 versus untreated controls.
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SBA plates, respectively, were not significantly different (data
not shown). Oral administration of L GG resulted in a 10-fold
increase in lactobacillus spp in caecal contents (1.0 (0.5)×107
CFU/g with antibiotics alone v 12 (3)×107 CFU/g caecal content
in antibiotics-L GG treated rats). However, caecal bacteroides
spp did not differ significantly among the treatment groups
(2.0 (1.4)×1010 with antibiotics alone v 2.7 (0.3)×1010 CFU/g
caecal content in the antibiotics-L GG treated group).
In vitro inhibition of bacterial adherence
B vulgatus adhered to IEC-6 cells after an incubation of three
hours. However, coculture of 109 B vulgatus and 109 L GG per
well significantly reduced the amount of adherent B vulgatus.
No effect was noted with concentrations of 108/well (fig 6) or
107/well L GG (data not shown).
DISCUSSION
Broad spectrum antibiotics can prevent as well as treat estab-
lished colitis in SPF B27 TG rats.11 Similar results were
obtained in other experimental colitis models in rats and
mice,11 26 27 emphasising the important role of intestinal bacte-
ria for induction and perpetuation of chronic intestinal
inflammation. Oral vancomycin/imipenem treatment resulted
in undetectable levels of bacteroides spp, which are capable of
selectively inducing colitis in B27 TG rats.10 13
We found that colitis relapsed within four weeks of stopping
vancomycin/imipenem treatment of established colitis in SPF
TG rats, resulting in disease relapse within four weeks with
gross and histological scores, MPO, and proinflammatory
cytokine levels nearly identical to untreated controls. This
finding correlated with the reappearance of luminal bacter-
oides spp as caecal bacteroides concentrations were not
significantly different in antibiotic treated rats versus un-
treated TG controls. These findings are in agreement with
clinical observations in Crohn’s disease which recurs after
stopping antibiotic treatment28 and can be explained by the
reappearance of disease inducing intestinal bacteria in geneti-
cally susceptible hosts.
A clinically relevant finding of our study was that oral L GG
treatment partially prevented relapse of colitis after antibiotic
treatment whereas L GG administration alone failed to show a
beneficial effect. This conclusion was supported by signifi-
cantly decreased gross caecal inflammation and colonic
histology scores, as well as a significant decrease in
non-specific inflammatory markers and cytokines, such as
caecal MPO, IL-1, and TNF in antibiotic-L GG treated SPF TG
rats versus other treatment groups. This is the first report of an
interactive effect of antibiotic and probiotic therapy in experi-
mental colitis. These results are in agreement with Gionchetti
et al in which relapsing pouchitis was prevented in 85% of
refractory pouchitis with an oral probiotic cocktail VSL#3,
which includes four strains of lactobacilli, three bifidobacteria
species, and Streptococcus salivarius subsp thermophilus after the
broad spectrum antibiotic rifaximin was stopped.20 Similarly,
prospective treatment with rifaximin followed by VSL#3
could also prevent endoscopic postoperative recurrence of
Crohn’s disease.29
Another major finding of our study was the specificity of
prevention of relapsing colitis by various lactobacillus species,
as demonstrated by the lack of efficacy of LP 299v in prevent-
ing colitis relapse in SPF TG rats after antibiotic treatment.
However, this result is in contrast with our previous reports
that oral LP 299v attenuated colitis in IL-10 KO mice,20 whereas
L GG had no effect.30 A preventive effect of LP 299v was also
shown in methotrexate induced enterocolitis in rats.31 These
contrasting responses suggest that different lactobacilli may
have variable host specificity or different efficacy in various
inflammatory conditions, indicating that not all probiotics are
equally protective in chronic experimental colitis. The concept
of selective dependency of beneficial effects of a probiotic bac-
terial species on the species and genetic background of the
host is similar to that of disease inducing bacteria.10 13 32 33
Other studies have reported primary beneficial effects of
probiotics in the treatment or prevention of human or experi-
mental intestinal inflammation. VSL#3 was able to treat
established colitis in IL-10 KO mice.25 The same cocktail has
also shown efficacy in an open labelled study on maintenance
therapy of ulcerative colitis.34 L GG can prevent relapsing
Clostridium difficile diarrhoea,19 traveller’s diarrhoea35 and
rotavirus infections in children.36 The non-pathogenic E coli
strain Nissle was shown to be as effective as low dose mesala-
mine in maintaining remission of ulcerative colitis.37 38
The protective mechanisms of probiotic bacteria are still
relatively unknown, with postulated effects on luminal micro-
ecology, mucosal barrier function, and immunoregulation. In
our study there was no decrease in the number of luminal
bacteroides spp, raising the possibility that some of the
protective effects of antibiotics-L GG could be explained by
immunomodulation. Not only does this therapy result in
decreased caecal proinflammatory cytokines IL-1β and TNF,
but it also increased mucosal IL-10. Lack of stimulation of
mucosal IL-10 by L GG or antibiotics alone indicate that
neither treatment is responsible for induction of IL-10. It is
possible that a combination of antibiotics and probiotics alters
the balance of enteric bacterial components, leading to altered
mucosal cytokine profiles. IL-10 is an immunoregulatory
cytokine, mainly produced by macrophages, dendritic cells,
and T regulatory 1 lymphocytes. However, we recently
reported that in caecal bacterial lysate stimulated MLN cells of
B27 TG rats as well as their non-TG littermates, IL-10 is
primarily produced by B cells.39 In vitro, lysates of VSL#3
stimulate IL-10 production and diminish TNF secretion by rat
splenocytes stimulated with caecal bacteria.40 In preliminary
data, it was demonstrated that DNA extracts of VSL#3 induce
IL-10 and exert protective immune responses.41 IL-10 can
inhibit antigen specific proliferation and cytokine secretion by
Th1 lymphocytes and has downregulatory effects on macro-
phages and dendritic cells, such as suppression of activation
and IL-12 production.42 43 IL-10 can also prevent interferon γ
induced disruption of colonic epithelial barriers.44 Defective in
vivo production of IL-10 results in spontaneous colitis in IL-10
KO mice in the presence of normal intestinal bacteria.7 45 Fur-
thermore, oral administration of Lactococcus lactis, engineered
to produce high colonic IL-10 levels, prevents the onset of
colitis in IL-10 KO mice as well as in dextran sodium sulphate
induced colitis.46 Thus stimulation of colonic IL-10 production
by the combination of antibiotic use and L GG colonisation
could have a variety of beneficial effects on mucosal
immunoregulation and barrier function.
Increased mucosal IL-10 production and decreased levels of
the proinflammatory cytokines IL-1β and TNF by the
Figure 6 Dose dependent inhibition of in vitro adherence of 109
CFU B vulgatus/2 ml well to IEC-6 cells by Lactobacillus rhamnosus
GG (L GG). Data represent concentrations (×103 CFU) of adherent B
vulgatus after three hours of incubation with IEC-6 monolayers in the
presence or absence of 108 or 109 CFU L GG/2 ml well. Values are
mean (SEM). **p<0.01 versus B vulgatus control.
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combination of antibiotics and L GG in our study are in agree-
ment with the findings of Ulisse et al who showed increased
IL-10 as well as decreased TNF and IFN-γ in pouch biopsies of
refractory pouchitis patients treated with VSL#3 after
antibiotic pretreatment.47 Similar to our findings, these
authors found that tissue IL-10 levels were unchanged in
inflamed pouches and were not affected by prior antibiotic
treatment.47 However, in IL-10 KO mice the probiotic cocktail
VSL#3 treated colitis with a concomitant decrease of mucosal
IFN-γ and TNF secretion,21 indicating that the beneficial
effects of probiotics in colitis can be mediated by factors other
than IL-10 induction.
Several non-immune protective mechanisms have been
described for probiotic bacterial species. These organisms can
exert growth inhibitory and bactericidal activities on entero-
toxigenic E coli.48 However, in our study caecal concentrations
of the disease inducing bacteroides spp were not significantly
decreased. Another potential protective non-immune mech-
anism involves inhibition of epithelial adherence of disease
inducing organisms. Intestinal bacteria compete with other
organisms for a limited number of epithelial receptors.
Increased amounts of colonic mucosal associated bacteria
were found in IL-10 KO mice28 as well as in mucosal biopsies
from IBD patients.49 Madsen et al also reported a relative lack
of adherent lactobacilli in IL-10 KO mice18 and restoration to
normal levels after probiotic treatment.19 21 Our in vitro cocul-
ture studies demonstrated that L GG decreased adherence of B
vulgatus to rat IEC-6 cells only at high concentrations of 109
CFU/ml, with no effects at lower doses. This result is in agree-
ment with in vitro studies by Madsen and colleagues21 and
Mack and colleagues25 in which probiotic bacteria prevented
the epithelial adherence of Salmonella dublin or enteropatho-
genic E coli. However, in our study, in vivo co-association of B
vulgatus and L GG did not prevent colitis in gnotobiotic TG rats.
This lack of effect by L GG in the dual association model could
be explained by the overwhelming colonisation capacity of the
disease inducing B vulgatus versus L GG, which were 100-fold
more frequent than L GG. It is possible that at this relatively
low in vivo luminal concentration L GG would not be able to
mediate protection by inhibiting epithelial adherence of B vul-
gatus, as equal concentrations of L GG were required to inter-
fere with B vulgatus epithelial adherence. Based on these find-
ings we postulate that protective effects by probiotics in SPF
TG rats could only be achieved by pretreatment of rats with
vancomycin/imipenem, which would result in a significant
decrease in B vulgatus11 before L GG treatment. However,
despite the prevention of colitis relapse by the combination
treatment of vancomycin/imipenem followed by L GG, this
treatment did not significantly reduce luminal bacteroides
spp, even though increased caecal lactobacilli spp was shown
by caecal culture. Taken together, reduction of luminal bacter-
oides spp could not explain the protective effects of broad
spectrum antibiotics followed by L GG. Prevention of colitis
relapse as well as immunomodulatory effects were shown only
with the combination treatment of vancomycin/imipenem
followed by L GG. It is possible that the combination treatment
promoted synergistic interaction of L GG with other endog-
enous probiotic species, resulting in disease protection. The
absence of these potential beneficial interactions with other
intestinal protective bacteria in gnotobiotic TG rats co-
associated with L GG and B vulgatus could also explain the lack
of efficacy of L GG in the prevention of colitis. Alternatively,
lack of exposure to lactic acid bacteria early in life in these
gnotobiotic rats may prevent stimulation of protective
responses by L GG at an older age.
In summary, oral L GG can prevent relapse of colitis in SPF
B27 TG rats after antibiotics are stopped whereas oral admin-
istration of L plantarum did not have any effect, demonstrating
the selective protective effects of two lactobacillus species. The
beneficial in vivo effects of L GG following antibiotics are pos-
sibly the result of enhanced IL-10 production. This is the first
study in experimental colitis in which antibiotics and probiot-
ics display synergistic in vivo effects. Restoring the microbial
balance between detrimental and protective luminal bacteria
by combining antibiotic and probiotic approaches may be the
most physiological approach to treat IBD and may alter the
natural history of these chronic relapsing diseases.
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